Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENVB Enveric Biosciences

Closed Good Friday 04-17 16:00:00 EDT

1.17

-0.06

-4.88%

盘后1.17

+0.000.00%

18:41 EDT

High1.22	Low1.14	Vol37.99K
Open1.20	D1 Closing1.23	Amplitude6.50%
Mkt Cap2.89M	Tradable Cap2.71M	Total Shares2.47M
T/O44.60K	T/O Rate1.64%	Tradable Shares2.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ENVB","market":"US","secType":"STK","nameCN":"Enveric Biosciences","latestPrice":1.17,"timestamp":1744920000000,"preClose":1.23,"halted":0,"volume":37993,"hourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.17,"latestTime":"18:41 EDT","volume":5,"amount":5.88,"timestamp":1744929686663},"delay":0,"floatShares":2314050,"shares":2471700,"eps":-19.039543,"marketStatus":"Closed Good Friday","change":-0.06,"latestTime":"04-17 16:00:00 EDT","open":1.2,"high":1.2199,"low":1.14,"amount":44603.348879799996,"amplitude":0.064959,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-19.039543,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.23,"preHourTrading":{"tag":"盘前","latestPrice":1.21,"preClose":1.23,"latestTime":"09:22 EDT","volume":369,"amount":455.7399075,"timestamp":1744896160149},"postHourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.17,"latestTime":"18:41 EDT","volume":5,"amount":5.88,"timestamp":1744929686663},"volumeRatio":1.4626850738224548,"impliedVol":6.7116,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ENVB","defaultTab":"news","newsList":[{"id":"2523946521","title":"Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946521","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946521?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:18","pubTimestamp":1743423536,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(4.83) per share which missed the analyst consensus estimate of $(0.23) by 2000 percent. This is a 78.1 percent increase over losses of $(22.05) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44559980/enveric-biosciences-q4-2024-gaap-eps-4-83-misses-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0},{"id":"2523945684","title":"Enveric Biosciences Inc: Qtrly Loss per Share $4.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945684?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA7CXZ0T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2523194586","title":"Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2523194586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523194586?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA7CXZ0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2523453309","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2523453309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523453309?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024. -- Advanced pre-IND and research activities including confirmation of oral. bioavailability and significant brain exposure for EB-003, a novel. including targeting of serotonergic receptors, supporting the potential. \"Enveric is entering 2025 with a clear mission -- enhance shareholder value by cementing our leadership position in the promising neuroplastogen field with the continued development of EB-003,\" stated Joseph Tucker, Ph.D., Director and CEO of Enveric. \"With EB-003, we believe Enveric is at the forefront of redefining the treatment of severe mental health conditions, an area of medicine that has been without substantial innovation for many years. We are now focused on completing the data package needed to file an Investigational New Drug  application for EB-003. After the completion of a pre-IND meeting with the U.S. Food and Drug Administration , and t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4099","ENVB","BK4555","TM","BK4585","BK4007","BK4588","03160"],"gpt_icon":0},{"id":"2523263245","title":"Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523263245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523263245?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 07:01","pubTimestamp":1743202860,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings SummaryEnveric Biosciences Inc ENVB.OQ reported a quarterly adjusted loss of $4.80 per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0},{"id":"2521286525","title":"Enveric Biosciences Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521286525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521286525?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 20:42","pubTimestamp":1742560923,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc  expected to post a loss of23cents a share - Earnings Preview Enveric Biosciences Inc ENVB.OQ ENVB.O is expected to show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q412O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENVB","RLMD","MYCOF","BK4202","SILO","NUMIF","SNPX","DRUG","FLHLF","MNMD","BK4168","ATAI","RVVTF","KTTA","BK4539","BETRF","AGNPF","CMND","PBM","NRXP","CYBN","CMPS","SPRC","ENTBF","QNTM","SEEL","BK4139","PSYGF","BK4007","GHRS","IXHL","MDXXF","PHRRF","ALID","OPTHF","BK4547","MIRA"],"gpt_icon":0},{"id":"2517830194","title":"Enveric Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517830194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517830194?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 03:08","pubTimestamp":1741288080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENVB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2025 14:08 ET (19:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0},{"id":"2517674341","title":"BRIEF-Enveric Biosciences Says Regains Compliance With Nasdaq Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2517674341","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517674341?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 00:30","pubTimestamp":1741278621,"startTime":"0","endTime":"0","summary":"BRIEF-Enveric Biosciences Says Regains Compliance With Nasdaq Bid Price RuleMarch 6  - Enveric Biosciences Inc ENVB.O:ENVERIC BIOSCIENCES INC - REGAINS COMPLIANCE WITH NASDAQ BID PRICE RULESource text: [ID:n0001493152-25-009336]Further company coverage: ENVB.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2517816459","title":"Enveric Biosciences launches RFP solicitation process for PsyAI trademark","url":"https://stock-news.laohu8.com/highlight/detail?id=2517816459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517816459?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 23:05","pubTimestamp":1741273546,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) announced the company will build on its recent business development momentum by soliciting Requests-For-Proposal for lic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-launches-rfp-solicitation-process-for-psyai-trademark?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-launches-rfp-solicitation-process-for-psyai-trademark?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2517661821","title":"Enveric Biosciences Inc: Period for Receiving Rfps Will Remain Open Until August 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2517661821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517661821?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 23:00","pubTimestamp":1741273213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1K4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2517166187","title":"Enveric Biosciences Launches Request-for-Proposals Solicitation Process for Psyai Trademark","url":"https://stock-news.laohu8.com/highlight/detail?id=2517166187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517166187?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 23:00","pubTimestamp":1741273213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2517161540","title":"Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161540","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517161540?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 23:00","pubTimestamp":1741273200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., March 06, 2025----Enveric Biosciences  , a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company will build on its recent business development momentum by soliciting Requests-For-Proposal  for license or sale of its PsyAI trademark portfolio as a means of maximizing value for an asset which is no longer strategic given the Company’s focus on drug development. This limited portfolio of US and Canadian trademark assets is held by its subsidiary, Enveric Biosciences Canada, Inc. Enveric has already received two expressions of interest in the licensing or sale of the portfolio of PsyAI marks, which has jump-started the RFP process for auctioning the marks.The period for receiving RFPs for license or sale of the PsyAI portfolio is now open and will remain open until August 31, 2025, with a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enveric-biosciences-launches-request-proposals-150000449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2517163285","title":"Enveric Biosciences Inc - Regains Compliance With Nasdaq Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517163285?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:31","pubTimestamp":1741271475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2514385815","title":"Enveric Biosciences CEO Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385815","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514385815?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 22:30","pubTimestamp":1740666600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., February 27, 2025----Enveric Biosciences  , a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an update on the Company’s development program and recent events. The full text of the letter follows.In 2024, we generated data that demonstrated EB-003’s ability to bind to the 5-HT2A receptor and induce neuroplasticity, the hypothesized mechanism of action for neuroplastogens. We also demonstrated EB-003 does not elicit a significant head twitch response  in mice. HTR is a behavioral model used to predict the likelihood of a drug candidate to induce hallucinations when administered to humans. We next produced preclinical data that conf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enveric-biosciences-ceo-issues-letter-143000088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ENVB"],"gpt_icon":1},{"id":"2514494853","title":"Upcoming Nvidia Earnings in Spotlight, Lifting US Equity Futures Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2514494853","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514494853?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 22:13","pubTimestamp":1740579182,"startTime":"0","endTime":"0","summary":"US equity futures rose ahead of Wednesday's opening bell as traders awaited earnings results from artificial intelligence chip market bellwether Nvidia (NVDA).The Dow Jones Industrial Average futures ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVDA",".IXIC","ENVB",".SPX","FLYW",".DJI","EQR","GO"],"gpt_icon":1},{"id":"2514536398","title":"Enveric Biosciences Prepares Presentation for February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514536398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514536398?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:57","pubTimestamp":1740578273,"startTime":"0","endTime":"0","summary":"Enveric Biosciences ( ($ENVB) ) just unveiled an update. Enveric Biosciences, Inc. announced that it has prepared presentation materials, which man...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enveric-biosciences-prepares-presentation-for-february-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enveric-biosciences-prepares-presentation-for-february-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","ENVB","ARKG","BK4544","BK4007"],"gpt_icon":0},{"id":"2514834648","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2514834648","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514834648?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:36","pubTimestamp":1740573419,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) shares soared 192% pre-bell Wednesday after the company said it received a US patent covering mescaline derivative compounds with potential application in addiction and neur","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4150","ENVB","BK4007","BHM","BK4084","OUT","CPHC","BK4228","BK4234","BK4215"],"gpt_icon":0},{"id":"2514333618","title":"US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333618","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514333618?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 19:06","pubTimestamp":1740567969,"startTime":"0","endTime":"0","summary":"U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/government/regulations/25/02/43967649/us-stocks-likely-to-open-higher-ahead-of-nvidia-earnings-sp-500s-four-day-fall-was-a-non-event-says-expert","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","TJX","GO","FLYW","DNA","AAP","AXON","KDP","SONO","VOO","NVDA","SPY","HD","LOW",".SPX"],"gpt_icon":1},{"id":"2514010746","title":"Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2514010746","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514010746?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 02:30","pubTimestamp":1740508200,"startTime":"0","endTime":"0","summary":"New patent for mescaline derivative compounds broadens Enveric’s potential to develop neuroplastogen therapeutics for addiction and neuropsychiatric disorders. CAMBRIDGE, Mass., February 25, 2025----Enveric Biosciences  , a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439  on January 14, 2025.Enveric Biosciences  is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enveric-biosciences-unveils-evm401-series-183000157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ENVB","DAT"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.enveric.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.3077},{"period":"3month","weight":-0.7797},{"period":"6month","weight":-0.8255},{"period":"1year","weight":-0.9116},{"period":"ytd","weight":-0.7824}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.173361},{"month":2,"riseRate":0.375,"avgChangeRate":0.066295},{"month":3,"riseRate":0.25,"avgChangeRate":-0.163046},{"month":4,"riseRate":0.25,"avgChangeRate":-0.108261},{"month":5,"riseRate":0.285714,"avgChangeRate":0.118959},{"month":6,"riseRate":0.714286,"avgChangeRate":0.054637},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.090005},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.109033},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.057156},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.242016},{"month":11,"riseRate":0.285714,"avgChangeRate":2.077595},{"month":12,"riseRate":0.375,"avgChangeRate":-0.125747}],"exchange":"NASDAQ","name":"Enveric Biosciences","nameEN":"Enveric Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enveric Biosciences(ENVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enveric Biosciences,ENVB,Enveric Biosciences股票,Enveric Biosciences股票老虎,Enveric Biosciences股票老虎国际,Enveric Biosciences行情,Enveric Biosciences股票行情,Enveric Biosciences股价,Enveric Biosciences股市,Enveric Biosciences股票价格,Enveric Biosciences股票交易,Enveric Biosciences股票购买,Enveric Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enveric Biosciences(ENVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction